To The Moon

Hey Tigers! 🐯

An AI megadeal should make an exciting headline. On November 2, it made a painful trading session: Marvell fell 12.7%, while Lumentum lost 18.6%.

My take: the important question is whether the combined business can earn enough to justify what shareholders are giving up. The structure matters immediately: Lumentum holders are being offered Marvell shares, so their deal value falls when Marvell falls.

1 | The Detail That Changes the Trade

Marvell announced an all-stock acquisition of Lumentum on November 2, 2026. Each LITE share would receive 4.500 MRVL shares. The announcement put implied enterprise value at $115 billion and reference consideration at approximately $1,132 per LITE share. That represented a 23.9% premium using October 28 unaffected prices.

That last date matters. The premium describes a historical comparison; it does not promise the same upside from today's price. And enterprise value is not the same thing as cash distributed to common shareholders.

The companies expect completion in the first half of calendar 2028, subject to shareholder and regulatory approvals and customary conditions. That leaves a substantial period in which earnings, valuations and transaction confidence can change.

2 | Why Would Both Stocks Fall?

For MRVL, my interpretation is that investors need a clearer return on the ownership being issued. Buying a complementary business can improve the product offering, but the acquired earnings must justify the larger share count and integration burden.

For LITE, the exchange ratio creates a direct transmission channel. A lower MRVL price reduces the market value of the stock consideration, even if the agreement stays exactly the same.

These mechanisms help explain why buyer and seller can fall together. They do not establish how much of Monday's decline came from each concern. The session alone cannot isolate deal-related selling from broader technology sentiment.

One correction to the usual acquisition debate: this is an all-stock agreement. Treating it as a $115 billion cash cheque funded entirely with fresh borrowing would misdescribe the transaction. The more immediate questions are ownership dilution, deal expenses, integration investment and the quality of future per-share earnings.

3 | The Industrial Logic Still Deserves Attention

The companies describe a combination of Marvell's connectivity and semiconductor capabilities with Lumentum's lasers, optical transceivers and optical circuit switching. Management projects more than $1 billion in annual run-rate cost synergies and non-GAAP EPS accretion in the first year after completion.

Those are management expectations, not realised savings or a guarantee of GAAP earnings growth.

My filter: ask how much benefit comes from recurring operating improvements, how long it takes to arrive, and what it costs to achieve. A stronger product portfolio becomes more valuable to shareholders when it wins profitable business and generates cash.

4 | LITE's Moving Deal Value

IBD reported November 2 closing prices of $171.41 for MRVL and $684.40 for LITE. Applying the exchange ratio gives gross stock consideration of approximately $771.35 per LITE share at that MRVL price.

That is around 12.7% above LITE's observed close, calculated as (4.5 × 171.41 ÷ 684.40 − 1). It is a snapshot of a moving spread, not a locked-in return. MRVL can decline before closing; completion can be delayed or fail.

My outlook: watch both prices together. A rising LITE price alongside a falling MRVL price can narrow the spread without improving the value of the consideration. A wider spread can reflect greater uncertainty as well as a potentially larger payoff if completion occurs.

5 | My Outlook for the Next Few Months

My base case is volatile trading while investors demand evidence that the strategic case can improve per-share returns. I would be cautious about calling a durable bottom from one large down day.

For MRVL, a recovery becomes more convincing if standalone earnings delivery holds up and management provides a credible integration timetable. Further weak guidance or an unclear return on integration spending would undermine that case.

For LITE, the near-term setup depends on MRVL's direction and confidence in completion. If the agreement fails, the 4.5-share formula stops being the right valuation anchor; standalone earnings, cash flow and valuation would take over.

These are conditional editorial scenarios for the coming weeks to three months. The sensitivity table illustrates transaction arithmetic; it is not a set of broker targets or a forecast trading range.

6 | What Would Change My Mind?

I would become more constructive with a clearer savings schedule, transparent integration costs and evidence that customer demand supports profitable growth. Shareholder voting materials and regulatory milestones would help assess completion risk.

I would become more cautious if management leans on adjusted EPS claims without showing the cash consequences, or if delays extend the wait for benefits.

The key test is whether each future share represents a more productive business. Until that becomes clearer, a cheaper price alone is a weak reason to assume the sell-off is over.

Tigers, What's Your Trade? 🐯

Would you rather own MRVL's combined-business upside or LITE's deal exposure? Which would change your view first: earnings, a detailed integration plan, or approval progress?